AU2772092A - Treatment of haemophilia - Google Patents

Treatment of haemophilia

Info

Publication number
AU2772092A
AU2772092A AU27720/92A AU2772092A AU2772092A AU 2772092 A AU2772092 A AU 2772092A AU 27720/92 A AU27720/92 A AU 27720/92A AU 2772092 A AU2772092 A AU 2772092A AU 2772092 A AU2772092 A AU 2772092A
Authority
AU
Australia
Prior art keywords
factor
haemophilia
subcutaneous injection
patient
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27720/92A
Other languages
English (en)
Inventor
George Gow Brownlee
Ann Justine Gerrard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Publication of AU2772092A publication Critical patent/AU2772092A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
AU27720/92A 1991-10-24 1992-10-20 Treatment of haemophilia Abandoned AU2772092A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9122609 1991-10-24
GB919122609A GB9122609D0 (en) 1991-10-24 1991-10-24 Improvements relating to the treatment of haemophilia

Publications (1)

Publication Number Publication Date
AU2772092A true AU2772092A (en) 1993-05-21

Family

ID=10703480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27720/92A Abandoned AU2772092A (en) 1991-10-24 1992-10-20 Treatment of haemophilia

Country Status (5)

Country Link
EP (1) EP0609293A1 (ja)
JP (1) JPH07502989A (ja)
AU (1) AU2772092A (ja)
GB (2) GB9122609D0 (ja)
WO (1) WO1993007890A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
WO2001082943A2 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
US20120148557A1 (en) * 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3684947D1 (de) * 1985-03-15 1992-05-27 Nat Res Dev Faktor-ix-protein.
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix

Also Published As

Publication number Publication date
GB9222012D0 (en) 1992-12-02
WO1993007890A1 (en) 1993-04-29
GB2260702B (en) 1995-09-20
EP0609293A1 (en) 1994-08-10
GB9122609D0 (en) 1991-12-04
GB2260702A (en) 1993-04-28
JPH07502989A (ja) 1995-03-30

Similar Documents

Publication Publication Date Title
EP0710114B1 (en) A coagulation factor viii formulation
US6103693A (en) Method for isolation of highly pure von willebrand factor
EP0035202B1 (en) Method of blood plasma fractionation
CA2161350C (en) Oxygen-reduced aqueous solution of factor viii
EP0526544B1 (en) Therapeutic uses of actin-binding compounds
EP0719154B1 (en) Activated factor viii as a therapeutic agent and method of treating factor viii deficiency
US7557188B2 (en) Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide
RU2166326C2 (ru) Комбинация тромболитически активных белков и антикоагулянтов
JPH10501522A (ja) 因子ｖｉｉｉまたは因子ｉｘの皮下、筋肉内または皮内投与用の製薬調合剤
JPH0597702A (ja) 安定化第ｖｉｉｉ因子調製物
EP0716611B1 (en) C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction
US4455300A (en) Fibronectin compositions
Aledort Treatment of von Willebrand's disease
AU2772092A (en) Treatment of haemophilia
Weiss et al. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid
JPH10504310A (ja) 生物学的に活性な化合物で患者を治療する方法
GB2079292A (en) Blood Clotting Factor Production
Clemens et al. Therapeutic effects of antivenom supplemented by antithrombin III in rats experimentally envenomated with Russell's viper (Daboia russelli siamensis) venom
JPH11199508A (ja) 臓器不全治療剤
CA2276564A1 (en) Modified c1 esterase inhibitor for blocking the infectiousness of hiv
JPH08268910A (ja) プロテインｃの皮下投与のための薬剤
JPH0618782B2 (ja) 組織プラスミノーゲン活性化因子製剤
JPH0925239A (ja) 脳血管攣縮治療剤
JPH09176041A (ja) α２プラスミンインヒビターを含有するＤＩＣ治療用薬剤